Q-omics provides the consensus-scored TRIB3 profile across patient tissues and cancer cell-line models. TRIB3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRIB3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, TRIB3 protein abundance shows 14,977 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, COAD, and LUAD as cancer lineages where TRIB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIB3 survival associations across molecular data types. TRIB3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIB3 RNA expression–survival associations across cancer types. High TRIB3 expression shows unfavorable associations in KIRP, BLCA, MESO, KIRC, HNSC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRIB3 RNA expression.
This table summarizes TRIB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIB3 shows higher tumor expression in COAD, KIRC, HNSC, KIRP, STAD and BLCA. The COAD box plot shows higher TRIB3 RNA expression in tumor versus normal tissue (log2 FC = +4.388, t-test p < 0.001).
This table shows molecular features associated with TRIB3 in patient tissues and cancer cell lines. In patient samples, TRIB3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
